ADA 2019—Dapagliflozin halts or slows kidney disease progression in T2D


  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dapagliflozin slowed or prevented nephropathy progression in a diverse patient population with type 2 diabetes (T2D), whether they had established atherosclerotic cardiovascular disease (CVD) or not.
  • Most participants in DECLARE-TIMI 58 trial had preserved renal function.

Why this matters

  • This trial shows benefit in patients regardless of atherosclerotic CVD status.

Key results

  • Median follow-up, 4.2 years (interquartile range, 3.9-4.4).
  • Sustained decline in estimated glomerular filtration rate (eGFR) to 60 mL/minute/1.73 m2 was reduced by 46% with dapagliflozin vs placebo: HR 0.54 (95% CI, 0.43-0.67; P<.0001>
  • Risk for end-stage renal disease/renal death also decreased with dapagliflozin: HR, 0.41 (95% CI, 0.20-0.82; P=.012).
  • Previously reported: renal-specific composite outcome risk reduced by 47% in dapagliflozin vs placebo: HR, 0.53 (95% CI, 0.43-0.66; P<.0001>
  • Authors report no significant interactions with most demographic, other measures.

Study design

  • Analysis of data for 17,160 participants in DECLARE-TIMI 58 (10 mg dapagliflozin vs placebo once daily), which included patients with T2D, HbA1c 6.5%-12.0%, established atherosclerotic CVD (40.6%) or multiple risk factors, creatinine clearance ≥60 mL/minute.
  • Follow-up: 4.2 years.
  • Funding: AstraZeneca.

Limitations

  • The cardiorenal composite was a secondary outcome.
  • For 1 of 2 primary outcomes (major adverse cardiovascular events), drug did not best placebo.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit